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Worldwide Trends in Survival From Common
Childhood Brain Tumors: A Systematic Review
Fabio Girardi, MD1; Claudia Allemani, PhD1; and Michel P. Coleman, MD1
abstract
PURPOSE The histology of brain tumors determines treatment and predicts outcome. Population-based survival
reﬂects the effectiveness of a health care system in managing cancer. No systematic review of worldwide
variation and time trends in survival from brain tumors in children is currently available.
PATIENTS AND METHODSWe considered longitudinal, observational studies comprising children diagnosed with
intracranial astrocytic or embryonal tumors. We searched six electronic databases from database inception to
September 30, 2018, using complex search strategies. The outcome measure was 5-year survival, estimated
through a time-to-event analysis. This study is registered with PROSPERO, number CRD42018111981.
RESULTS Among 5,244 studies, we identiﬁed 47 eligible articles that provided 228 survival estimates. Only ﬁve
studies were entirely or partially conducted in low-income or middle-income countries. Five-year survival from
embryonal tumors increased from 37% in 1980 to approximately 60% in 2009. Although survival for me-
dulloblastoma improved substantially (from 29% to 73% during 1959-2009), survival for primitive neuro-
ectodermal tumors wavered over time (1973-2009) and between countries. Five-year survival from astrocytoma
changed very little over the 27 years between 1982 and 2009 (from 78% to 89%). Interpretation of the literature
was made difﬁcult by the heterogeneity of study designs.
CONCLUSION Survival has improved for embryonal tumors, but little change has been observed for astrocytic
tumors. We found a striking gap in knowledge about survival from childhood brain tumor subtypes in middle-
income and low-income countries, where half of these tumors are diagnosed. Larger studies are needed,
including in under-represented countries and based on standardized data collection, to provide up-to-date
survival estimates.
J Global Oncol. © 2019 by American Society of Clinical Oncology
Licensed under the Creative Commons Attribution 4.0 License
INTRODUCTION
Primary tumors of the CNS in children are rare. The
estimated world-standardized incidence rate in 2018
was 12 cases per million, ranging from 1.8 in Melanesia
to 36.0 in North America.1 Despite their rarity, primary
CNS tumors were estimated to be the second most
important cause of childhood cancer–related deaths
after leukemia. The estimated world-standardized mor-
tality rate in 2018 was 0.7 deaths per million, varying
between 0.04 in Tanzania and 2.4 in Honduras.1
Incidence and mortality are essential indicators of the
cancer burden in a given population, but the duration
of survival also accounts for the dynamic nature of
the process between diagnosis and death. Therefore,
population-based survival is the most appropriate
measure to assess the overall effectiveness of a health
care system in managing a given cancer.2,3 The third
cycle of the CONCORD program (CONCORD-3) found
wide disparities in survival among more than 700,000
patients who were diagnosed with a primary brain
tumor in 58 countries worldwide during the 15-year
period of 2000-2014. Five-year net survival for all
childhood brain tumors combined ranged from 29% in
Brazil to approximately 80% in several European
countries.4 International disparities in survival may
result from obstacles in access to surgery, radiother-
apy, and chemotherapy.5-8 Such inequalities will in-
evitably result in failure to diagnose and treat brain
tumors adequately, ultimately leading to premature
deaths.9
CNS tumors comprise tumors of the brain, the spinal
cord, and the meninges, but brain tumors are by far
the largest group. Brain tumors vary widely in terms of
histology and clinical behavior. Histology plays a piv-
otal role in treatment planning, and treatment needs
are speciﬁc to each tumor subtype. Therefore,
a breakdown of the observed disparities in survival by
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histology is warranted to help shape cancer control plans.
In the ﬁfth cycle of the EUROpean CAncer REgistry based
study on survival and care of cancer patients (EUROCARE-
5) study, which involved children diagnosed during 2000-
2007 in 27 European countries, the average 5-year
observed survival was 95% for children diagnosed with
pilocytic astrocytoma and 65% for those affected by me-
dulloblastoma. This study showed very wide international
disparities. For instance, among children diagnosed with
a brain tumor deﬁned asWHO grade III or IV, 5-year survival
ranged from 36% in Bulgaria to 66% in Finland.10
To our knowledge, no summary of the scientiﬁc evidence
on population-based survival for the main subtypes of brain
tumor in children is available. We aimed to ﬁll this gap in
knowledge by conducting the ﬁrst systematic review on
time trends and geographic variation in survival from brain
tumors.
PATIENTS AND METHODS
We considered longitudinal, observational studies that
provided estimates of population-based survival, by his-
tology, for children (mainly those age 0-14 years) diagnosed
with a primary brain tumor, either malignant or non-
malignant. We excluded studies that only included patients
with a CNS tumor in anatomic sites other than the brain
because of their rarity and the paucity of data. We also
excluded studies that only presented survival estimates for
all histologies combined. Studies had to be based on pri-
mary data drawn from population-based cancer registries.
To maximize geographic coverage, we did not discard
studies presenting hospital-based estimates if those esti-
mates were likely to be representative of a given country or
territory (eg, a single referral center or a comprehensive
network of referral centers) and if no population-based
estimate was available. We also excluded clinical trials or
clinical series, because these study designs only include
selected patients. Studies were eligible if they included
estimates of the survival probability from a time-to-event
analysis. To improve comparability between studies, only
those presenting survival estimates at 5 years after the
diagnosis were included.
We searched six databases (Dissertation and Theses
Global, Embase, Medline, Open Grey, Scopus, and Web of
Science) from database inception to September 30, 2018,
using predeﬁned search strategies that included terms
related to the disease under study, the statistical method,
and the study design. A professional librarian at the London
School of Hygiene and Tropical Medicine reviewed the
search strategies (Appendix Table A1).
There were no restrictions relating to language or publi-
cation status. However, we excluded studies published
before 1995, because the versions of the reference clas-
siﬁcations were too early to allow comparability with sub-
sequent editions.
According to the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (ie, PRISMA) approach
(Fig 1),11 potentially eligible studies were evaluated at three
progressive levels: title, abstract, and full text. When eli-
gibility was unclear, we reached an agreement through
discussion.
For each eligible study, we extracted data on the tumor
subtypes included and the reference classiﬁcation used for
tumor deﬁnitions (eg, International Classiﬁcation of Dis-
eases for Oncology, third edition [ICD-O-3]).12 We col-
lected, when available, speciﬁcations of data quality
indicators: the proportions of microscopically veriﬁed tu-
mors, poorly speciﬁed/unspeciﬁed morphologies, patients
lost to follow-up, and whether diagnoses based on death
certiﬁcate only or autopsy were excluded. We recorded the
CONTEXT
Key Objective
To explore what is known about time trends and global variation in population-based survival from common childhood brain
tumors.
What Is Known
Five-year survival from medulloblastoma increased from 23% to 73% during 1960-2010, while survival from astrocytoma
(nonmalignant and malignant combined) persisted in the range of 80%-90% (1970-2010). Scarce data were available
from low-income and middle-income countries, where most childhood brain tumors are currently diagnosed.
Relevance
Our systematic review of real-world, population-based survival estimates may inform clinicians about expected outcomes in
unselected populations of children with brain tumor. The available estimates, however, do not cover countries with limited
resources, where obstacles in access to care may result in suboptimal treatment. Global initiatives aiming to improve
survival of children with brain tumor are underway, and they require a more recent, wide-ranging survival benchmark,
which can be obtained only through larger studies using the same protocol for data collection, centralized data quality
checks, and the same statistical methodology.
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5-year survival probabilities for each eligible subtype and,
when available, the corresponding survival estimates for
each calendar period. Last, for each cancer registry, we
sought information on the proportion of the population
covered and on the completeness of ascertainment.
For studies considering several calendar periods, we ab-
stracted each survival estimate separately. The calendar
periods examined varied widely between studies, so we
described trends by using the middle year of the corre-
sponding time interval. Given the sparseness of data for
some very rare subtypes, we focused on the most frequent
morphologies, namely astrocytic and embryonal tumors.
Morphologic groupings and deﬁnitions also differed be-
tween studies. We combined different deﬁnitions for the
same subtype under a common descriptor (Appendix
Table A2).
RESULTS
We assessed 5,244 records for eligibility. Forty-seven
studies were included in the systematic review. For each
study, we detailed the following: location, completeness of
ascertainment, population covered, calendar period for
incident cases, age range, quality indicators available,
reference classiﬁcation, and outcome measure (Table 1).
In thirty studies (64%), patients were age 0-14 years; they
were 0-15 years in four studies and were 2 years or younger
in three studies. Nine studies (19%) included individuals
age 20 years or younger, and the upper age limit in one
Records screened for eligibility at abstract and title level
(n = 4,145)
Duplicates excluded
(n = 1,099)
Records assessed for eligibility at full-text level
(n = 329)
Records excluded
(n = 3,816)
Records excluded
    Presenting, for a given country or region,
        hospital-based estimates in presence of
        population-based estimates
    Considering countries/regions or populations
        included in more recent augmented studies
        (eg, larger sample size, longer follow-up, or
        larger geographic coverage)
    Published before 1995
    Ineligible design or non-informative reports
    Ineligible outcome measure
    Ineligible topography
    Ineligible morphology
    Ineligible age group
    Presenting estimates for children and adults
        combined 
(n = 282)
    (n = 4)
          
          
  (n = 43)
           
           
           
  (n = 23)
  (n = 48)
  (n = 58)
    (n = 9)
  (n = 68)
  (n = 15)
  (n = 14)
Studies included in the systematic review
(n = 47)
Potentially eligible records
    Records identified through Dissertation and Theses Global
    Records identified through Embase
    Records identified through Medline
    Records identified through Open Grey
    Records identified through Scopus
    Records identified through Web of Science
    Records identified through additional sources   
   (n = 339)
(n = 1,422)
   (n = 724)
     (n = 19)
(n = 2,509)
   (n = 226)
       (n = 5)
(N = 5,244)
FIG 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) ﬂowchart.
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FIG 2. Five-year survival (%) from embryonal tumors and medulloblastoma. Automated Childhood Cancer Information
System (ACCIS) consortium: Denmark, Estonia, Finland, France, Germany, Hungary, Iceland, Italy, Netherlands,
Slovakia, Slovenia, Spain, Switzerland, United Kingdom (UK), Norway. EUROpean CAncer REgistry based study on
survival and care of cancer patients (EUROCARE)-3 consortium: Austria, Czech Republic, Denmark, England, Estonia,
Finland, France, Germany, Iceland, Italy, Malta, Netherlands, Norway, Poland, Scotland, (continued on following page)
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study was 24 years. Studies using nonstandard age deﬁ-
nitions were included here, because the study populations
comprised mainly children.
Nineteen studies (40%) had regional population coverage,
10 (21%) were based on nationwide registries, eight (17%)
were international studies based on both regional and
national registries, and the information was not available in
10 studies. Only ﬁve studies were entirely or partially
conducted in low-income or middle-income countries.13-16
The calendar period for incident cases ranged from 1954 to
2014 (Table 1). The eligible studies collectively provided
228 survival estimates.
For patients diagnosed with embryonal tumors as a broad
histology group, 5-year survival increased substantially
during the 30 years between 1980 and 2009, from 37% in
1980 to approximately 60% in 2009.14,17-26 In most
countries, the survival probability was 50% or lower until
1997.17-26 Despite this positive trend, there were remark-
able geographic disparities. Around 2000, there was a 26%
gap in 5-year survival between the Southern and Eastern
Europe (SEE) consortium, including middle-income coun-
tries such as Belarus, Bulgaria, and Ukraine (40%),14 and
the EUROCARE-5 consortium, which includes all of themost
afﬂuent European countries (66%; Fig 2).23
Five-year survival from medulloblastoma increased from
29% to 73% during the 50 years between 1959 and
2009.27-46 In Denmark, Italy, and Slovakia, survival was
10% or less until 1972. In Denmark and Italy, survival
increased sharply during the following decade (approxi-
mately 40% in 1982), while survival in Slovakia was still 26%
in 1985.28-30 In most of the European countries, the survival
probability was 60% or more after 199210,27,35,38-42,47; in the
United States, similar or higher values were observed
in 1977.31 Five-year survival from medulloblastoma in
Tunisia was less than 27% in 1997, and it was zero in
Uganda in 2007 (n = 14 patients).13,16 Survival in children
younger than age 2 years was 50% or lower and did not
change over time (Fig 2).45,46,48,49
Five-year survival from primitive neuroectodermal tumors
(PNETs) ﬂuctuated in the range of 27%-52% in most
European countries (1973-2009) without a monotonic
trend.10,35,36,38-42,45,50-52 In two studies conducted in En-
gland and France, survival values were not in line with
those observed in other European countries, but CIs were
wide.39,50 In the United States, 5-year survival ranged be-
tween 47% and 81% during 1977-2009.42,45,51,52 These
values were higher than those observed in Europe during
the four decades between 1973 and 2009 (24%-47%).
Five-year survival from PNET in infants (age 1 year or
younger) varied between zero and 33% (1990-2004), but
data were scant and inconsistent (Fig 3).45,49,53
For children diagnosed with atypical teratoid/rhabdoid tu-
mor, a rare subtype of embryonal tumor, 5-year survival in
Germany increased from 21% to 42% during 2001-2009,
but CIs overlapped.39 In the United States54 and the
EUROCARE-5 consortium,10 the survival probability during
2004-2008 was 30% or less (Fig 3).
Astrocytoma as a broad histology group was the most
commonly adopted deﬁnition. Five-year survival was 71%
or lower during 1970-1980,29,30,32,50,51 and it increased
slightly over three decades, from 78% in 1982 to 89% in
2009.14,17,19,20,22-25,29-32,35,37,47,50,51,55 During 1982-1996,
when the ICD-O-2 was in force,56 5-year survival for as-
trocytoma ranged between 72% and 82% in most
countries.19,21,30-32,35,38,50,51 In the EUROCARE-4 study23
(which used the ICD-O-312), 5-year survival for astrocy-
toma (1995-2002) in Central Europe, Northern Europe,
Southern Europe, the United Kingdom, and Ireland was
also approximately 75% when all behaviors were consid-
ered, but it decreased by 10% when nonmalignant tumors
were excluded. In Eastern Europe, the survival probability
was approximately 65% regardless of tumor behavior.23
Similarly, in the EUROCARE-5 study, 5-year survival for
malignant astrocytoma was in the range of 60%-65%
during 2000-2007.47 Five-year survival from astrocytoma in
India was 39% in 1996, whereas survival in the SEE
consortium was similar to that of other European regions
(Fig 4).14,15
Five-year survival for low-grade astrocytoma (WHO grades I
and II combined) was 80% or more in Europe, the United
States, and Israel,25,36,40,44 but it was slightly less than 80%
in Tunisia.13 For patients diagnosed with pilocytic astro-
cytoma during 1981-1991, 5-year survival was in the range
of 88%-91% in England, Wales, the United States, and
Southeastern Europe. During 1995-2004, 5-year survival from
pilocytic astrocytoma increased to 95% or more in the United
States, Israel, and the EUROCARE-5 consortium,10,42,44,52,57
but it remained unchanged in Southeastern Europe.57 Five-year
FIG 2. (Continued). Slovakia, Slovenia, Spain, Sweden, Switzerland, Wales. EUROCARE-4 (continued on following
page)consortium: Austria, Belgium, Czech Republic, Denmark, England, Estonia, Finland, France, Germany,
Iceland, Ireland, Italy, Malta, Netherlands, Northern Ireland, Norway, Poland, Portugal, Scotland, Slovakia,
Slovenia, Spain, Sweden, Switzerland, Wales. Southern and Eastern Europe (SEE) consortium: Belarus, Bulgaria,
Croatia, Cyprus, Greece, Malta, Portugal, Romania, Serbia, Slovenia, Turkey, Ukraine. AIRTUM (Associazione
Italiana Registri Tumori). EUROCARE-5 consortium: Austria, Belgium, Bulgaria, Croatia, Czech Republic, Den-
mark, England, Estonia, Finland, France, Germany, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Malta,
Netherlands, Northern Ireland, Norway, Poland, Portugal, Scotland, Slovakia, Slovenia, Spain, Sweden, Swit-
zerland, Wales. The CI is not displayed when the study did not provide it.
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survival for diffuse astrocytomawas in the range of 60%-78% in
Europe and Japan during 1981-2004 (Fig 5).10,33,58
Five-year survival for high-grade astrocytoma (WHO grades
III and IV combined) was 20%-30% in France, Germany,
and Sweden (1990-2004).25,36,40 Five-year survival prob-
ability for anaplastic astrocytoma was 30% or lower in
Europe,10,33,42 Japan,58 South Korea, and the United
States,42,55 but it was 55% in Israel.44 Five-year survival for
glioblastoma was in the range of 8%-20% in Europe,10,33
Israel,44 Japan,58 South Korea, and the United States31,42,55
(Fig 5). For both low-grade and high-grade astrocytomas,
there was no improvement in the observed outcomes
during the 25 years between 1981 and 2004.
Among 47 studies, only 11 (23%) speciﬁed the com-
pleteness of case ascertainment. One third (36%) did not
provide details on data quality. Twenty-six studies (55%)
speciﬁed at least the proportion of microscopically veriﬁed
tumors, and seven of them only included patients with
microscopically veriﬁed tumors (Appendix Table A3). Four
of the eight international studies speciﬁed the proportion of
histologically conﬁrmed brain tumors,10,14,42,57 whereas the
others reported a proportion for all childhood tumors
combined (Appendix Table A3).18,19,23,47 Seven studies
(15%) did not specify the reference classiﬁcation, and two
did not clarify the version of the ICD-O or the International
Classiﬁcation of Childhood Cancer (ICCC) that was used
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FIG 3. The 5-year survival (%) from primitive neuroectodermal tumor and atypical teratoid/rhabdoid tumor.
EUROCARE-5 consortium: Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, England, Estonia,
Finland, France, Germany, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Malta, Netherlands, Northern Ireland,
Norway, Poland, Portugal, Scotland, Slovakia, Slovenia, Spain, Sweden, Switzerland, Wales. The CI is not displayed
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FIG 4. Five-year survival (%) from astrocytoma (broad group). EUROpean CAncer REgistry based study on survival
and care of cancer patients (EUROCARE-3) consortium: Austria, Czech Republic, Denmark, England, Estonia,
Finland, France, Germany, Iceland, Italy, Malta, Netherlands, Norway, Poland, Scotland, Slovakia, Slovenia, Spain,
Sweden, Switzerland, Wales. EUROCARE-4 consortium: Austria, Belgium, Czech (continued on following page)
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(Table 1). Five of the 22 studies using the deﬁnition “as-
trocytoma” (broad histology group) did not elucidate
whether they included only malignant tumors or both
malignant and nonmalignant tumors (Appendix Table
A3).15,17,20,29,35 Thirty-nine studies (83%) provided esti-
mates of all-cause survival (ie, observed). Only eight pro-
vided relative survival estimates, adjusted for background
mortality (Table 1).
FIG 4. (Continued). Republic, Denmark, England, Estonia, Finland, France, Germany, Iceland, Ireland, Italy, Malta,
(continued on following page)Netherlands, Northern Ireland, Norway, Poland, Portugal, Scotland, Slovakia,
Slovenia, Spain, Sweden, Switzerland, Wales. Southern and Eastern Europe (SEE) consortium: Belarus, Bulgaria,
Croatia, Cyprus, Greece, Malta, Portugal, Romania, Serbia, Slovenia, Turkey, Ukraine. EUROCARE-5 consortium:
Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, England, Estonia, Finland, France, Germany,
Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Malta, Netherlands, Northern Ireland, Norway, Poland, Portugal,
Scotland, Slovakia, Slovenia, Spain, Sweden, Switzerland,Wales. TheCI is not displayedwhen the studydidnot provide
it. UK, United Kingdom.
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FIG 5. Five-year survival (%) from astrocytoma WHO grade I and II, pilocytic astrocytoma, diffuse astrocytoma,
astrocytoma WHO grade III and IV, anaplastic astrocytoma, and glioblastoma. EUROpean CAncer REgistry based
study on survival and care of cancer patients (EUROCARE-5) consortium: Austria, Belgium, Bulgaria, Croatia,
Czech Republic, Denmark, England, Estonia, Finland, France, Germany, Hungary, Iceland, Ireland, Italy, Latvia,
Lithuania, Malta, Netherlands, Northern Ireland, Norway, Poland, Portugal, Scotland, Slovakia, Slovenia, Spain,
Sweden, Switzerland, Wales. The CI is not displayed when the study did not provide it. SEE, Southern and Eastern
Europe; UK, United Kingdom.
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DISCUSSION
To our knowledge, this is the ﬁrst systematic review syn-
thesizing trends and geographic variation in survival for the
most common morphologic subtypes of brain tumor in
children. Five-year survival for embryonal tumors increased
remarkably during the 1980s and the 2000s, and the
change was driven mostly by an improvement in the out-
come of patients diagnosed with medulloblastoma. Survival
from astrocytic tumors changed very little, regardless of
WHO grade.
Only ﬁve studies included patients diagnosed in low-
income or middle-income countries (Belarus, Bulgaria,
India, Montenegro, Romania, Serbia, Tunisia, Turkey,
Uganda, Ukraine).13-16 In this setting, the magnitude of the
survival gap depended on country and histology, albeit the
largest deﬁcit was seen for embryonal tumors. In high-
income countries, where nearly all of the studies were
conducted, outcomes were similar. However, in the United
States, survival from the most common embryonal tumors
improved earlier than elsewhere.
Low-grade gliomas represent approximately one third of all
CNS tumors in children. They are biologically distinct from
low-grade gliomas seen in adults, and progression to higher-
grade lesions rarely occurs.59 Pilocytic astrocytoma is the
most common glioma subtype in children.60 We adopted
different levels of granularity in the histology deﬁnitions, but
data for speciﬁed astrocytic tumors were sparse. Most
studies presented survival estimates on the basis of the
second tier of the ICCC, group IIIb (ie, astrocytoma).61 For
tumors deﬁned as astrocytoma (broad group), corre-
sponding to the ICCC group IIIb, 5-year survival was ap-
proximately 90% during 2004-2009. During a comparable
period, survival from pilocytic astrocytoma (WHO grade I)
was nearly 100%. Pilocytic astrocytoma therefore is probably
responsible for the favorable outcome observed in the
broader group, because diffuse astrocytoma, anaplastic
astrocytoma, and glioblastoma combined only constituted
approximately 30% of astrocytic tumors in children.10
The current recommendation is to present survival in
children separately for each ICCC group. Even though
pilocytic astrocytoma is predominant in children, we believe
that the adoption of a broad category, such as astrocytoma
(ICCC-3 group IIIb), does not fully account for international
variations in survival, and it may actually attenuate the
observed trends and differences. We chose to report sur-
vival at 5 years, because that is the most commonly re-
ported time landmark, and to facilitate comparisons
between studies. Low-grade gliomas are often indolent
tumors that progress slowly, even after partial resection or
biopsy.62 In a large US study that included nearly 3,500
children (age 0-20 years) diagnosed with low-grade glio-
mas during 1973-2005, the survival probability at 10 years
for WHO grade I and grade II tumors was approximately
90% and 80%, respectively.63 Therefore, outcomes for this
cancer subtype may be better described with longer-term
survival estimates.
A remarkable proportion of studies adopting the deﬁnition
of astrocytoma (as a broad histology group) did not clarify
the tumor behavior. This information is necessary to in-
terpret trends correctly. In the second edition of the ICD-O
(in force from 1990),56 pilocytic astrocytoma was coded as
malignant (behavior code 3), but, in the third edition (in
force from 2000), it was attributed a borderline behavior
(code 1).12 In studies considering patients diagnosed
during 1982-1996, which used ICD-O-2, survival from
astrocytoma was likely to be high as a result of the inclusion
of pilocytic astrocytoma, which was deﬁned at that time as
a malignant tumor. In brain tumors, location is more im-
portant than it is for tumors at other anatomic sites, because
location affects clinical presentation, diagnosis, treatment,
and morbidity. Therefore, though pilocytic astrocytoma was
reclassiﬁed as a nonmalignant tumor in ICD-O-3, most
studies published after 2000, when ICD-O-3 was adopted,
included all brain tumors, regardless of behavior. As a re-
sult, survival estimates from these studies were in fact
comparable to those in earlier reports that were based on
ICD-O-2. In EUROCARE-5, however, survival from astro-
cytoma in Eastern Europe was similar, regardless of
whether tumors with borderline behavior were included or
not.23 This ﬁnding suggests under-registration of non-
malignant brain tumors in Eastern Europe.
Medulloblastoma is the most common embryonal tumor,
with a peak incidence at approximately 7 years of age.
Treatment includes a combination of surgery, craniospinal
irradiation, and chemotherapy. In this review, the steepest
gain in survival from medulloblastoma occurred before
1992, possibly reﬂecting improvement in radiotherapy
techniques.64 The effect of adding chemotherapy with
lomustine, cisplatin, and vincristine after radiotherapy was
ﬁrst assessed in a phase II trial in the 1990s.65 In light of
the observed beneﬁt, the use of chemotherapy became
standard. In the 1990s and 2000s, 5-year survival in-
creased from approximately 60% to 70%. This ﬁnding may
be the joint result of improved surgical management and
incorporation of chemotherapy into routine clinical
practice.66 Survival from medulloblastoma was much lower
in low-income and middle-income countries than in high-
income countries. This disparity may reﬂect the lack of
access to optimal multimodality treatment.5-8
In three studies, medulloblastoma was grouped with
PNETs, even though ICD-O-3 was given as the reference
classiﬁcation.50-52 As a result, survival estimates were
higher than those for PNET only.35,38,41,42 Infratentorial
medulloblastoma and supratentorial PNET are distinct
entities, described as separate morphologies in the second
edition of the WHO classiﬁcation of CNS tumors (2002).67
Because medulloblastoma has a more favorable outcome
than PNET, its inclusion in a wider group mislabeled as
PNET will bias the survival estimates upward.
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Two studies deﬁned astrocytoma, not otherwise speciﬁed
(NOS), as a separate morphologic entity, perhaps to allow
for a generic diagnosis of unspeciﬁed astrocytic tumor.10,33
In the United States, the proportion of astrocytic tumors
registered as astrocytoma NOS decreased from 47% to
13% during 1973-2005.63 The WHO classiﬁcation does not
recognize astrocytoma NOS as a distinct deﬁnition. Diffuse
astrocytoma and astrocytoma NOS share the same ICD-O-3
code, but the WHO classiﬁcation retains only the ﬁrst of
the two descriptors.12,60 Therefore, we grouped together
the survival estimates, which proved comparable (70%-
80%).10,33
In most of the studies reviewed here, indicators of data
quality were often missing or incomplete. The proportion of
tumors that had been microscopically veriﬁed was the most
widely available parameter. Few studies reported any ad-
ditional descriptors, such as the proportion of patients who
were lost to follow-up before the end of the study. The
proportion of microscopically veriﬁed tumors pertains not
only to disease management, namely whether surgery or
biopsy was performed, but also to whether the cancer
registry had access to pathology reports.68 The proportions
of microscopically veriﬁed brain tumors were in the range of
73%-93% in the SEE consortium (1983-2014) and 71%-
100% in the EUROCARE-5 study (2000-2007).10,14
The proportion of brain tumors that are microscopically
veriﬁed is typically lower than for other types of cancer,
because brain tumors aremore lethal and patients are often
too unwell to undergo an invasive diagnostic procedure;
advanced surgical expertise also is required. If the pro-
portion of tumors that are histologically unclassiﬁed is high,
survival estimates for speciﬁc morphologies may be biased,
because patients with histologically conﬁrmed disease are
likely to have higher survival than those whose tumors could
not be pathologically conﬁrmed.
Similarly, information on the completeness of ascertain-
ment of brain tumors was very often missing. In most of the
studies for which this information was available, it was
usually reported as nearly complete (95% or more). This
parameter is important to assess whether the patients in-
cluded in the study are representative of all patients with
brain tumors in the population of a given region or
country.69
In most of the studies (83%), survival was reported only as
observed survival, without taking into account death as
a result of causes other than the brain tumor (background
mortality). If competing risks of death are not properly
accounted for, survival estimates will be biased downward.
Background mortality also varies widely between countries
and over time, so valid international comparisons require
that background mortality is incorporated in the survival
estimates. However, nearly all of the studies were con-
ducted in afﬂuent countries, where background mortality in
children has generally been very low for several decades.
The distortion in international comparisons of brain tumor
survival in children is thus likely to be small.
This systematic review was affected by several limitations.
First, we aimed to give a comprehensive account of vari-
ations in brain tumor survival by including all of the relevant
histology categories. However, very few studies were
available for some categories, precluding robust conclu-
sions on time trends and geographic variations in survival.
Second, almost all the studies were based on regional
rather than national data. Assuming that regional survival
estimates are applicable to the whole country may not be
wise in the presence of regional disparities in access to or
provision of treatment within a given country. However, data
from most of these regions were later included in wider
studies with national or international coverage. Survival
estimates from those studies were in line with those pre-
viously reported at regional level, suggesting that ﬁndings
from the earlier, smaller studies were indeed generalizable
to the country. Finally, the dates and the length of calendar
periods in which the patients had been diagnosed also
varied widely between studies. To allow an orderly pre-
sentation of time trends, we referred to the central year for
any given time interval, but we were not able to compare the
average annual increment or decrement in survival be-
tween calendar periods of different, and often overlapping,
lengths. Improvements in survival were nevertheless limited
mainly to embryonal tumors, and they occurred over an
extended period, so the international comparisons may be
considered reasonably informative.
In conclusion, there is a staggering gap in evidence about
survival from the most common types of childhood brain
tumor in low-income and middle-income countries. In-
terpretation of the literature is hampered by the very wide
heterogeneity between the designs of the various studies
and by the quality of the available data.
We highlight the fact that the ICCC does not allow accurate
description of variation in survival from astrocytic tumors,
because it does not encompass stratiﬁcation by grade. The
goal of the WHO Global Initiative for Childhood Cancer is to
improve survival worldwide for six cancer subtypes, in-
cluding low-grade gliomas.70 In the context of brain tumors,
future assessment of the progress of this global effort will
require that an informative, up-to-date survival benchmark
for low-grade gliomas is set. Ultimately, the ICCC should be
revised.
The 2016 WHO classiﬁcation of Tumors of the Central
Nervous System has redeﬁned or replaced several di-
agnostic entities or subgroups by incorporating molecular
classiﬁers.71 For instance, PNET is no longer included in
the diagnostic dictionary, and medulloblastoma is now
genetically deﬁned. Future comparisons of survival will
have to account for these changes, but capacity-building
and resources are needed to extend the use of this
classiﬁcation, both in clinical practice and in cancer
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registries, especially in low-income and middle-income
countries.
Larger international studies that include currently under-
represented countries are warranted, and robust survival
estimates are only possible through use of the same
protocol for data collection, centralized and stringent data
quality checks, and application of the same statistical
methodology—including appropriate life tables to correct
for the risk of death as a result of causes other than
cancer.
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APPENDIX
TABLE A1. Strategy for Searching Embase
Search Term and Order
Exposure domain: central nervous system tumor
1 “central nervous system tumo?r*".mp.
2 "central nervous system cancer*".mp.
3 "central nervous system neoplasm*".mp.
4 "brain cancer*".mp.
5 "brain tumo?r*".mp.
6 "brain neoplasm*".mp.
7 "cns cancer*".mp.
8 "cns tumo?r*".mp.
9 exp central nervous system neoplasms
10 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9
Outcome domain: survival
11 "survival".mp.
12 “survival analysis”.mp.
13 exp survival rate
14 11 or 12 or 13
Study design domain: longitudinal observational studies
15 "cancer registr*".mp.
16 “international comparison*”.mp.
17 exp epidemiology
18 exp life tables
19 exp registries
20 15 or 16 or 17 or 18 or 19
21 exp clinical trial, phase i or exp clinical trial, phase ii or exp
clinical trial, phase iii or exp clinical trial, phase iv or exp
controlled clinical trial or exp randomized controlled trial
or exp double-blind method or exp random allocation or
exp single-blind method
22 “randomized controlled trial”.mp.
23 "clinical trial".mp.
24 "clinical trial, phase i".pt.
25 "clinical trial, phase ii".pt.
26 "clinical trial, phase iii".pt.
27 "clinical trial, phase iv".pt.
28 "controlled clinical trial".pt.
29 "randomized controlled trial".pt.
30 "clinical trial".pt.
31 21 or 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30
32 20 not 31
(Continued in next column)
TABLE A1. Strategy for Searching Embase (Continued)
Search Term and Order
Combination of the above domains
33 10 and 14 and 32
34 "comment".pt.
35 "letter".pt.
36 "editorial".pt.
37 exp case reports
38 exp comment
39 exp letter
40 exp editorial
41 34 or 35 or 36 or 37 or 38 or 39 or 40
42 33 not 41
43 animals
44 humans
45 43 not 44
46 42 not 45
Abbreviations: mp, multi-purpose (the database looks for the
keywords in the default set of ﬁelds); exp, explosion (the database
searches not only for the medical subject heading but also for many
related terms); pt, publication type.
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TABLE A2. Morphology Grouping Strategy in the Systematic Review
Morphology Grouping Strategy in the Systematic Review Deﬁnitions As Adopted in the Studies
Embryonal tumor Embryonal tumor
Medulloblastoma Medulloblastoma
Ependymoma and medulloblastoma
Primitive neuroectodermal tumor PNET
Supratentorial PNET
Atypical teratoid/rhabdoid tumor AT/RT
Astrocytoma (broad group) Astrocytoma
Astrocytoma + pilocytic astrocytoma
IIIb (ICCC-3)
Astrocytoma WHO grade I/II Astrocytoma WHO grade I/II
Astrocytoma low grade
Pilocytic astrocytoma Astrocytoma WHO grade I
Pilocytic astrocytoma
Diffuse astrocytoma Astrocytoma WHO grade II
Diffuse astrocytoma
Fibrillary astrocytoma
Astrocytoma NOS
Astrocytoma WHO grade III/IV Astrocytoma WHO grade III/IV
Astrocytoma high grade
Glioblastoma and anaplastic astrocytoma
Anaplastic astrocytoma Anaplastic astrocytoma
Astrocytoma WHO grade III
Glioblastoma Glioblastoma
Abbreviations: ICCC-3, International Classiﬁcation of Childhood Cancer, third edition; NOS, not otherwise speciﬁed.
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